Phase 2 Alopecia Areata Trial, Recruiting NCT04986579 Sponsor: Dana-Farber Cancer Institute Condition: Alopecia Areata
Back to Alopecia Areata

Phase 2 Alopecia Areata Trial, Recruiting

NCT04986579
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are a man or woman who has been diagnosed with breast cancer that has spread to other parts of the body (metastatic), and you are still able to carry out basic daily activities (confirm with trial site regarding activity level assessment)
  • You are 18 years old or older
  • You still have hair at the time of joining the trial (you have not already lost your hair)
  • You are planned to receive at least 4 cycles of one of these specific chemotherapy treatments: Sacituzumab govitecan, Trastuzumab deruxtecan, or Eribulin, at the full standard doses
  • If you choose to be in the scalp cooling group, you must start using the Paxman Scalp Cooling System from your very first chemotherapy dose

Who may not be able to join:

  • You have a known blood cancer, such as leukemia or lymphoma
  • Cancer has spread to your scalp
  • You are already experiencing hair loss before the trial begins
  • You have a condition called cold agglutinin disease or cold urticaria (conditions where your body reacts badly to cold temperatures)
  • You are scheduled to receive very high-dose chemotherapy that wipes out your bone marrow
  • You have a personal medical diagnosis of migraines, cluster headaches, or tension headaches, or have been prescribed medication for these — though if this was a past problem that has fully resolved, the lead doctor may still consider you (confirm with trial site)
  • You have lichen planus or lupus
  • You are currently receiving any other cancer treatments alongside the ones listed above

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Elahe Salehi, DNP, ANP-BC, Dana-Farber Cancer Institute

Phone: 617-632-3800

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
7 October 2021
Est. completion
1 June 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Hair Loss Rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov